MarketCap
Facebook
X
Telegram
Interpace Biosciences Net Income | IDXG
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Interpace Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.6 M | 6.7 M | 1.95 M | -22 M | -14.9 M | -26.5 M | -26.7 M | -12.2 M | -12.2 M | -8.33 M | -11.4 M | -16.1 M | -4.56 M | -25.5 M | -11.9 M | -6.81 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.6 M | -26.7 M | -10.4 M |
Quarterly Net Income Interpace Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 M | 721 K | - | 911 K | -640 K | 1.65 M | - | 1.68 M | 2.44 M | 708 K | - | -614 K | 175 K | 351 K | - | -14.2 M | -3.94 M | -2.25 M | - | -3.56 M | -3.45 M | -4.21 M | -8.14 M | -6.23 M | -5.58 M | -6.49 M | -10.7 M | -7.45 M | -5.3 M | -3.33 M | -4.3 M | -3.13 M | -2 M | -3.28 M | - | -3.4 M | -6.39 M | 2.33 M | - | -8 M | -2.84 M | -5.3 M | - | -5.4 M | -7.49 M | -4.61 M | - | -4.45 M | -2.66 M | -1.61 M | - | -2.14 M | -883 K | 2.13 M | - | -1.02 M | -439 K | -272 K | - | -202 K | -895 K | -550 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.44 M | -14.2 M | -2.85 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M |  USA |
 |
Syneos Health
SYNH
|
266 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K |  Israel |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
-33.5 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
-1.86 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
42.5 M | - | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
836 M | $ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
1.3 B | $ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
-24.2 M | $ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 3.16 | 4.29 % | $ 103 K | USA |
 |
Biodesix
BDSX
|
-35.3 M | $ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
-26.4 M | $ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
22.7 M | $ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
-60.5 M | $ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 78.47 | 2.8 % | $ 4.18 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
-3.78 M | $ 1.61 | -1.55 % | $ 4.69 M | USA |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
ICON Public Limited Company
ICLR
|
229 M | $ 204.67 | 1.5 % | $ 16.1 B |  Irlanda |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
-55.3 M | $ 13.2 | -0.38 % | $ 139 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
-41.7 M | $ 2.4 | -11.93 % | $ 9.56 M | Israel |
 |
Myriad Genetics
MYGN
|
-366 M | $ 5.97 | -5.17 % | $ 553 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-7.03 M | $ 4.73 | -5.49 % | $ 3.72 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 16.85 | 2.18 % | $ 2.16 B | USA |
 |
OPKO Health
OPK
|
-226 B | $ 1.72 | -1.71 % | $ 1.29 B | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 2.3 | -5.35 % | $ 690 M | USA |
 |
Neogen Corporation
NEOG
|
-7.9 M | $ 11.75 | 0.6 % | $ 2.56 B | USA |
 |
Precipio
PRPO
|
-363 K | $ 18.95 | 2.02 % | $ 30.4 M | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 15.76 | 1.32 % | $ 1.41 B | USA |
 |
Sotera Health Company
SHC
|
77.9 M | $ 16.01 | 0.88 % | $ 4.55 B | USA |
 |
Quidel Corporation
QDEL
|
810 M | $ 10.69 | -16.78 % | $ 450 M | USA |
|
Centogene N.V.
CNTG
|
-35.5 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
-12 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-811 M | - | 0.12 % | $ 80.1 M | China |
 |
Aspira Women's Health
AWH
|
-12.8 K | - | -6.19 % | $ 10.5 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.14 M | - | - | $ 9.42 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 25.62 | 0.55 % | $ 573 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 120.83 | 0.18 % | $ 7.23 B | USA |
 |
Organovo Holdings
ONVO
|
-13.8 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
23.6 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
241 M | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
20.9 M | - | - | $ 2.69 B | USA |